ZYME vs. PTGX, CPRX, CRNX, MTSR, VKTX, MOR, SRRK, KYMR, MLTX, and IMVT
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Metsera (MTSR), Viking Therapeutics (VKTX), MorphoSys (MOR), Scholar Rock (SRRK), Kymera Therapeutics (KYMR), MoonLake Immunotherapeutics (MLTX), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.
Zymeworks vs. Its Competitors
Protagonist Therapeutics (NASDAQ:PTGX) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.
Protagonist Therapeutics has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 1.9% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Zymeworks received 3 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 67.89% of users gave Zymeworks an outperform vote while only 61.55% of users gave Protagonist Therapeutics an outperform vote.
Protagonist Therapeutics has a net margin of 52.76% compared to Zymeworks' net margin of -182.75%. Protagonist Therapeutics' return on equity of 34.68% beat Zymeworks' return on equity.
Protagonist Therapeutics currently has a consensus price target of $65.44, suggesting a potential upside of 17.95%. Zymeworks has a consensus price target of $21.00, suggesting a potential upside of 62.20%. Given Zymeworks' higher possible upside, analysts clearly believe Zymeworks is more favorable than Protagonist Therapeutics.
In the previous week, Protagonist Therapeutics had 5 more articles in the media than Zymeworks. MarketBeat recorded 6 mentions for Protagonist Therapeutics and 1 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.27 beat Protagonist Therapeutics' score of 0.95 indicating that Zymeworks is being referred to more favorably in the news media.
Protagonist Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
Summary
Protagonist Therapeutics beats Zymeworks on 13 of the 17 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
This page (NYSE:ZYME) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy ZYME Stock Free ZYME Stock Alerts